MeiraGTx

Update in progress

MGTX (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

MeiraGTx Holdings plc is a clinical‑stage genetic medicines company focused on serious diseases. It develops ocular gene therapies for inherited retinal diseases and other eye conditions, neurodegenerative disorders, and xerostomia. Lead programs include AAV‑AQP1 for xerostomia/Sjögren’s, AAV‑GAD for Parkinson’s, and AAV‑RPE65 for retinal dystrophy, with additional AAVs in Phase 1/2 and preclinical work. Partners include Johnson & Johnson Innovation and Hologen Limited. Founded 2015; New York.

Company score

Sentiment: 0.50; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.12; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.06; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.05; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.28; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive